CONTEXT: Report of data presented at the EuroPCR annual meeting on Medtronic’s Symplicity Renal Denervation system. Results from a registry involving nearly 3,000 patients showed significant and clinically meaningful reductions Continue Reading
CONTEXT: Publication of a retrospective chart review on the effectiveness of Halaven (eribulin mesylate) in metastatic breast cancer | One of the limitations of this study is that detailed safety Continue Reading
CONTEXT: Results from the analysis of registry involving around 6,000 TAVR patients in the US. IMPACT: Low READ TIME: 2 mins Quality Level Mean [1 – 10]: 6 1. “(TVT) Continue Reading
CONTEXT: Big news in the world of Big data. When Action, Flatiron Health, IQVIA, Syapse and Tempus all get together to form a coalition with the aim of promoting RWE Continue Reading
CONTEXT: Report of the summit held in April 2021 by the Centre for Medical Cannabis on the future of medical cannabis in Britain. The report includes reference to a Continue Reading
CONTEXT: This paper published in the AJMC describes the findings from a retrospective chart review of migraine sufferers taking Erenumab | Data from 5 US headache centres only (n = Continue Reading
CONTEXT: Report of a study published in the Annals of Hematology detailing the use of RWE to conduct a head-to-head comparison of treatments used in relapsed/refractory multiple myeloma. Retrospective analysis Continue Reading
CONTEXT: Report of a poster presentation at the American College of Cardiology’s 70th Annual Scientific Session on P2Y12 inhibitors, FXa inhibitors and dabigatran. Results of a retrospective analysis of claims databases Continue Reading
CONTEXT: An interview article with a UK based company looking to bring “natural” psilocybin medicines to market through RWE studies and dodge the usual RCT regulatory routes. One to watch Continue Reading
CONTEXT: A report on how innovation in the MedTech business is enabling health care providers to transform patient care to a more de-centralised model | US only IMPACT: Low READ Continue Reading
